



Available online at <https://s-epub.in/index.php/trp/index>

Pharma Research

An International Peer Reviewed, Indexed Journal

[10.62655/s-epub.2026.v18.i01.pp9-16](https://s-epub.in/index.php/trp/index)

PUBLIC PERCEPTION OF GENERIC MEDICINES AND WILLINGNESS TO SUBSTITUTE

LUCIE NOVOTNY^{1*}, CHIARA MANCUSO², ALEKSANDRA GRABOWSKI³

Affiliation

¹Department of Social Pharmacy, Vysocina Institute of Pharmaceutical Chemistry, Jihlava, Czech Republic

²Department of Social Pharmacy, Valtellina Centre for Pharmacology, Sondrio, Italy

³Department of Social Pharmacy, Warmia Institute of Pharmaceutical Sciences, Olsztyn, Poland

*Corresponding author: Lucie Novotny, l.novotny@vipc.cz

ORCID iD: Lucie Novotny 0000-0001-1872-5649; Chiara Mancuso 0000-0001-3467-6269; Aleksandra Grabowski 0000-0001-3526-5103

Article info

Received date:11-09-2025

Accepted date:18-01-2026

Published date:08-04-2026

ISSN;0975-8216

Keywords:

Generic medicines, Public perception, Generic substitution, Bioequivalence, Patient attitudes

1. INTRODUCTION

Generic medicines account for the majority of prescriptions dispensed in many health systems, yet the confidence patients place in them does not always match the volume in which they are used. A generic product contains the same active substance, in the same strength and dosage form, as an originator already on the market, and it reaches the shelf once patents and data exclusivity have lapsed. Savings follow because the generic manufacturer does not repeat the full clinical programme [1]. Governments therefore encourage generic

Abstract

Generic medicines make up most prescriptions in many health systems, but public confidence in them is uneven and often limits how far substitution policies succeed. This narrative review draws on published surveys, qualitative studies, trials and regulatory documents to describe how lay people view generic products and what shapes their willingness to accept a substitute. It reports no new data. The literature shows broad acceptance when cost savings and professional endorsement are present, alongside a persistent minority who doubt quality. Appearance changes, expectation effects and the attitudes of prescribers and pharmacists all contribute. Most evidence is cross-sectional and self-reported, so behaviour at the counter remains poorly measured.

prescribing and pharmacy-level substitution as a way of controlling expenditure without narrowing access [2]. Whether those policies work in practice depends heavily on whether the person holding the box is prepared to

accept a different name, colour or shape of tablet in place of the one they know.

This review brings together published work on how the public views generic medicines and how willing people are to accept substitution. It does not report a new survey or any new participant data. The emphasis is on consumer and patient opinion, with prescribers and pharmacists included because their advice shapes it [3, 4]. Reported studies come from Europe, North America, Asia and the Middle East, and they use different questionnaires, sampling methods and definitions of what counts as willingness, so comparisons across them are made with caution. Regulatory evidence on equivalence is described first, since public doubts are easier to judge against what the data actually show about clinical performance.

Two broad patterns recur across the literature. Most surveyed members of the public say they would take a generic if a doctor or pharmacist recommended it, and many add that they would do so mainly to save money [5, 6]. At the same time, a persistent minority regard generics as weaker, less safe or made to a lower standard, and that belief is often held without any personal experience of a problem [4, 6]. Reconciling those two findings, high stated acceptance alongside lingering unease, is the central task of the sections that follow, and it explains why policy built on price alone has produced uneven results.

2. REGULATORY EQUIVALENCE

Approval of a generic medicine rests on pharmaceutical equivalence and bioequivalence. In practice, regulators ask the applicant to show that the generic delivers the active substance into the circulation at a rate and extent within accepted limits of the reference product. The usual criterion is a 90% confidence interval (CI) for the ratio of geometric means lying between 80.00% and 125.00% for the area under the concentration-time curve (AUC) and for peak concentration ($C_{\max}$) [7, 8]. The studies are typically crossover trials in healthy volunteers. Guidance from the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the World

Health Organization (WHO) differs in detail but follows the same logic [7, 8, 9].

Before bioequivalence is even tested, a generic dossier has to show that the product is made to the same quality standards as the originator. The applicant must demonstrate the same active substance, strength and route of administration, comparable dissolution behaviour, acceptable impurity limits and manufacture under good manufacturing practice at an inspected site [7, 9]. Excipients may differ, and this is where much of the visible difference arises: the binder, filler or coating that alters the colour or taste of a tablet has no therapeutic role but is the first thing a patient notices. Regulators treat such differences as acceptable provided that dissolution and exposure remain comparable. The public rarely hears this part of the explanation, and a cautious patient who has noticed only the changed tablet has little reason to infer the rest.

Analyses of this evidence are reassuring on average. The FDA's own regulatory overview of bioavailability and bioequivalence shows how closely the pharmacokinetic comparison is scrutinised before approval, so large average differences between a generic and its reference are not expected [10]. A systematic review and meta-analysis of generic and brand-name cardiovascular drugs found little evidence of a clinically meaningful difference [11], and cohort data on generic statins point the same way [12]. Biowaivers based on the Biopharmaceutics Classification System (BCS) allow in vivo studies to be skipped for some highly soluble, highly permeable substances, and the scientific case for extending them to further classes has been argued in the literature [13].

Averages are not certainty for every drug. Medicines with a narrow therapeutic index (NTI), such as some antiepileptics and anticoagulants, attract the strongest concern because small shifts in exposure may matter. A meta-analysis of seizure outcomes with generic and brand-name antiepileptic drugs found no consistent signal of harm, though the authors noted that the trials were small and not designed to test switching between generics [14]. Regulators in several countries apply tighter limits to these products. For

public perception the lesson is that caution has a rational core in a few cases, and blanket reassurance may sound dismissive to patients who have spent years stabilising on one product [14].

Quality failures do occur, and sceptical patients sometimes cite them. Isolated reports of substandard products, particularly in markets with weaker oversight, travel a long way in public discussion. Pricing rules differ widely between countries, and so does what patients see at the counter [15]. In low- and middle-income countries (LMIC), equivalence on paper depends on enforcement, inspection of manufacturing sites and pharmacovigilance that actually functions. A health system that can show its generics are tested after marketing, and publishes the results in plain language, is better placed to earn trust than one that simply asserts equivalence, and that openness costs little.

3. PUBLIC AND PATIENT PERCEPTIONS

A systematic review of perceptions in the general population, doctors and pharmacists found that the public was generally less confident in generics than health professionals, and that confidence rose with familiarity [4]. A separate critical review of consumer studies described a mixture of beliefs: generics were accepted as cheaper and as a reasonable alternative, yet were frequently judged less effective, less safe or of lower quality than brands [6]. German work reached a similar position, with patients seeing generics as adequate for minor illness and being warier where the condition was serious or long-term [16]. The recurring themes and the studies that reported them are summarised in table 1.

Table 1: Published findings on public and professional views of generic medicines

Source type	Main finding reported	Ref.
Systematic review Public, doctors, pharmacists	Public less confident than professionals; confidence rose with familiarity.	[4]
Critical review Consumer studies	Generics accepted as cheaper, yet often judged less effective or less safe.	[6]

Source type	Main finding reported	Ref.
German primary care study	Generics accepted for minor illness; wariness for serious or chronic disease.	[16]
US patient survey	Lower cost raised willingness; many still believed brands worked better.	[5]
Policy reviews Demand-side measures	Reference pricing and INN prescribing shift use; effect on belief unclear.	[17, 18]
Nordic patient interviews	Saving welcomed; anxiety when substitution occurred without explanation.	[19, 20]
Randomised switch study	Belief in a change to generic increased reported side effects.	[21, 22]
Pill appearance cohorts	Changes in colour or shape linked to discontinuation after infarction and in epilepsy.	[23, 24]
Systematic review Determinants of use	Prescriber attitudes, patient beliefs and system rules all recur as determinants of generic use.	[3]
Pharmacist studies	Support in principle; concern about frequent product changes and workload.	[25, 26]

Price is the strongest and most consistent reason for accepting a generic. In a US survey, patients told that a generic would cost less were more willing to switch, though many still believed that brand drugs worked better and a notable share thought generics were less safe [5]. Interviews in Norway and Finland describe patients who welcomed the saving but felt anxious when substitution happened without explanation [19, 20]. Wording seemed to matter. When generics were described as the same medicine with the same active ingredient, acceptance rose, whereas a description that stressed cost alone appeared to reinforce the idea of a cheaper, lesser product [5, 6].

Where people get their information matters as much as what the information says. Surveys indicate that patients draw on their doctor and pharmacist, on family and friends, on advertising and on the internet, and that these sources do not always agree with one another [6, 27]. Media reports of product recalls or

manufacturing failures, usually involving a handful of products, can leave a lasting general impression that copies are riskier, even though originators are recalled too. Accounts from several countries suggest that a single bad story told by a relative may count for more with a patient than a regulator's published figures [4, 27]. Clear, locally relevant information from a source the patient already trusts is therefore likely to be more persuasive than national campaigns.

Appearance is a quieter source of doubt. Generic tablets differ from the originator in colour, shape, size and markings, because trade dress is protected. Patients who rely on those cues to recognise their medicines may conclude they have been handed the wrong drug, or may end up taking two supplies of what is in fact the same one. Observational data link changes in pill appearance after myocardial infarction to a greater likelihood of stopping treatment [23], and a comparable association has been reported for antiepileptic drugs [24]. A change in appearance is therefore an adherence problem as much as a perception problem, and the two are hard to separate.

Expectation also changes what people feel. In a randomised study, participants who believed they had been switched to a generic reported more side effects and less benefit than those who believed they were still on the brand, although the same product was given in both cases [21]. This is a placebo effect, in which negative expectations produce real symptoms [22, 28, 29]. It does not mean that patients are imagining things; the experience is genuine even when the pharmacology is unchanged. It does mean that the way a switch is communicated can influence the outcome, and a pharmacist who says nothing may leave an unhelpful expectation in place.

Older adults and people taking several medicines face a particular problem. Each repeat prescription may be filled with a product from a different manufacturer, depending on stock and price, so that the same drug appears in a changing succession of shapes and colours. Pharmacists in Sweden described confusion among older customers who could no longer match tablets with the instructions they had been given [25]. Cohort

data on cardiovascular medicines suggest that repeated changes carry a greater risk of stopping treatment than a single one [23]. For these patients, willingness to substitute may fall not because of any belief about quality but because the burden of keeping track becomes unmanageable, and the remedy lies in dispensing practice rather than in persuasion.

4. PROFESSIONAL ATTITUDES

Public views do not form in isolation. A systematic review of the factors that influence generic use identified prescriber attitudes as a recurring determinant, alongside patient beliefs and the rules of the health system [3]. Earlier work reported that most physicians considered generics equivalent in principle but were less sure about particular classes, and that they rarely discussed substitution in any detail with patients [30]. In Ireland, a comparison of doctors and pharmacists suggested that pharmacists held the more favourable views, which fits their training in bioequivalence and their daily handling of the products [26].

Pharmacists are the point of contact at which substitution actually happens. Swedish research describes pharmacists as supportive of generics in principle but unhappy about the administrative burden, the frequent changes in the product supplied and the confusion among older patients [25]. Where a pharmacist's margin grows with price, or where there is a fear of losing a customer's goodwill, the incentive to recommend a generic weakens, and several policy reviews point to this misalignment [17, 18]. Training and clear protocols help. Patients appear most receptive when the explanation is short and confident, not apologetic, and when the pharmacist names the active substance so that the patient can check it against earlier packets and against the prescription held at home.

Physician behaviour influences willingness indirectly. Patients who hear a doctor express reservations tend to share them, and a prescription written by brand name closes off substitution altogether in many systems [3, 30]. Demand-side measures such as prescribing by international non-proprietary name (INN), reference pricing and

co-payment differentials all aim to steer behaviour, and their effect on perception is less clear than their effect on market share [17, 18]. Evidence for incentive schemes aimed at prescribers is mixed, and some doctors regard financial targets for generic use as an intrusion on clinical judgement that makes them more guarded rather than less. Public education campaigns have been tried, with modest and short-lived gains where they stood alone [18].

System rules set the stage on which these attitudes play out. Some countries oblige pharmacists to offer the cheapest equivalent unless the prescriber or patient objects, others make substitution voluntary, and a few allow the prescriber to block it by writing a brand name or ticking a box on the form [17, 18]. A review of prescribing-efficiency policies in Europe found that the mandate alone did not guarantee uptake: pharmacists needed adequate payment, prescribers needed reassurance, and patients needed information [17]. Low- and middle-income settings face the added problem of weak enforcement of quality standards and patchy supply, which makes scepticism more rational. Economic studies still show substantial savings when substitution is adopted for high-volume chronic medicines, which is why governments continue to press the case [2, 31].

Professional education is a neglected piece of the picture. Pharmacy curricula usually cover bioequivalence and biopharmaceutics in some depth, while medical training may treat the topic briefly, which could partly explain why pharmacists report more favourable views than physicians in some surveys [26, 30]. Continuing education on how generic approval works, delivered by regulators and professional bodies, is a low-cost response that has seldom been evaluated. If doctors are to reassure patients credibly, they need to be able to explain in a sentence or two what equivalence means and what it does not, without resorting to jargon.

5. DRIVERS OF WILLINGNESS TO SUBSTITUTE

Putting the findings together, willingness to substitute looks like the product of several

interacting factors. Perceived equivalence and trust in the person giving advice come first, cost and insurance design follow, and prior experience and the manner of communication shape the rest [5, 6, 19]. The balance of themes among the studies in table 1 is shown in fig. 1. No single factor explains acceptance on its own, no study has measured all of them in the same population, and the relative weight of each appears to differ between systems, which is one reason why a policy that works in one country may disappoint in another [17, 18].




Fig. 1: Number of entries in table 1 by theme

Cost deserves separate comment because it cuts both ways. Where patients pay out of pocket, price differences are visible and acceptance is high, though this can leave an impression that generics are for people who cannot afford better. Where insurance covers most of the cost, the incentive to switch is weaker and any worry about quality weighs more heavily [18]. Reference pricing and tiered co-payments produce clearer behavioural responses than information alone, and economic modelling suggests that the largest savings depend on uptake of generics for chronic medicines taken for years [2, 31].

Communication looks like the most modifiable factor. Short, specific messages seem to work better than general reassurance: that the active ingredient is identical, that the product has been tested for equivalence, and that its appearance may differ [5, 23]. Framing a switch positively reduces reports of side effects in experimental settings [21, 29]. A written note explaining the change, with the name of the active substance kept visible on the label, helps patients who take many tablets. None of this is complicated, but it takes time that a busy counter does not always have, and trials of structured counselling remain scarce [6, 31]. Pharmacy

staff who are trained and paid to give this explanation, and who are not rushed, seem to achieve better acceptance than those who are not.

Trust in institutions sits underneath many of these individual factors. People who trust their regulator, their insurer and their pharmacy are more inclined to accept that a product bearing an approval mark is what it claims to be, whereas people who have met erratic supply or poor service in public facilities may project that experience onto the medicine itself [4]. Reviews of consumer studies describe this as a kind of generalised confidence rather than a specific belief about bioequivalence [6, 27]. If the point holds, interventions that improve reliability of supply, openness about testing and consistency of staff advice may influence acceptance of generics more than any amount of explanation about pharmacokinetics.

Chronic and acute conditions probably call for different approaches. For a short course of an antibiotic or analgesic, most patients show little concern about which manufacturer supplied the box. For long-term treatment of epilepsy, heart disease or depression, a change can feel like a risk to hard-won stability, and the wariness reported in some surveys is concentrated there [14, 16]. Offering continuity, for example by dispensing the same generic on each refill where supply allows, may calm that concern better than argument. Pharmacies that record the brand supplied and tell patients when it changes are already doing a version of this [23, 24].

6. LIMITATIONS AND FUTURE DIRECTIONS

The literature has clear weaknesses. Most studies are cross-sectional questionnaires, often in a single city or clinic, with convenience samples and no validated instrument. Willingness is usually stated, not observed, so the gap between what people say and what they do at the counter is poorly measured [4, 6]. Definitions of generic differ between countries, which complicates comparison; in some markets a branded generic is the default, so the contrast people have in mind is not originator against copy at

all [18, 27]. Publication bias towards findings of scepticism cannot be excluded, and so cannot the opposite problem, in which studies that find easy acceptance seem less newsworthy and are written up less often.

Measurement choices deserve a closer look. Many questionnaires ask hypothetical questions of the kind, would you accept a generic if your doctor advised it, and the answer is shaped by the wording, by the wish to appear reasonable and by the setting in which the form is completed [5, 6]. Studies that offered a real price difference produced different results from those that did not [19]. Instruments rarely distinguish between the generic as a concept and the specific product being dispensed, although patients may feel quite differently about the two. Mixed-method designs that pair a survey with interviews and with dispensing data would give a more reliable picture than any of these alone [4, 27].

Several gaps stand out. Longitudinal studies that follow patients through an actual switch, recording adherence, symptoms and satisfaction, would say more than attitude surveys do [23, 24]. Work in low- and middle-income settings is thin, even though those populations stand to gain most from affordable medicines [15]. Little is known about how online information and social media shape belief. Trials that test communication scripts, pharmacist training and placebo-aware counselling would move the field from description to intervention, and they should report outcomes that matter to patients as well as acceptance rates [21, 22].

7. CONCLUSION

Public views of generic medicines are mixed rather than hostile. Most people will accept a generic when it saves money and when a trusted professional endorses it, and the regulatory and clinical evidence supports that acceptance for the great majority of products [7, 10, 11]. A minority remain doubtful, and their doubts are fed by unfamiliar terminology, changes in tablet appearance, expectation effects and the reservations of some prescribers [3, 21, 23]. Equivalence on paper does not carry itself into the consultation room unaided, and the evidence

reviewed here suggests that explanation, not assertion, is what moves opinion.

Practical gains seem most likely from better communication, continuity of supply for long-term treatment and consistent professional messages, supported by visible post-marketing surveillance [6, 12]. Stronger evidence will need prospective studies of real switches, wider geographical coverage and trials of counselling methods that report patient outcomes as well as acceptance. Until then, policy that relies on price alone is likely to meet resistance among the patients whose confidence it most needs, and those patients are often the ones with the most to gain from affordable treatment [2, 18].

8. ABBREVIATIONS

AUC-Area under the concentration-time curve, BCS-Biopharmaceutics Classification System, CI-Confidence interval, C_{max} -Peak plasma concentration, EMA-European Medicines Agency, FDA-US Food and Drug Administration, INN-International non-proprietary name, LMIC-Low- and middle-income countries, NTI-Narrow therapeutic index, WHO-World Health Organization

9. FUNDING

Nil

10. AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

11. CONFLICT OF INTERESTS

Declared none

12. REFERENCES

1. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997–2000. *Ann Intern Med* 2005;142:891–7.
2. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Kesselheim AS, *et al.* State generic substitution laws can lower drug outlays under Medicaid. *Health Aff* 2010;29:1383–90.
3. Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. *Res Social Adm Pharm* 2018;14:619–27.
4. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. *BMJ Open* 2015;5:e008915.
5. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. *Health Aff* 2009;28:546–56.
6. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic critical review of consumers' perceptions: the 'generic' case. *BMC Med* 2015;13:173.
7. Committee for Proprietary Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence CPMP/EWP/QWP/1401/98. London: EMEA; 2001.
8. US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs, general considerations. Silver Spring: FDA; 2014.
9. World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for drug regulatory authorities. Geneva: WHO; 1999.
10. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, *et al.* Bioavailability and bioequivalence: an FDA regulatory overview. *Pharm Res* 2001;18:1645–50.
11. Manzoli L, Flacco ME, Boccia S, La Vecchia C, Ioannidis JPA, Bosetti C, *et al.* Generic versus brand-name drugs used in cardiovascular diseases. *Eur J Epidemiol* 2016;31:351–68.
12. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, *et al.* Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. *Ann Intern Med* 2014;161:400–7.
13. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, *et al.* Summary workshop report: biopharmaceutics classification system, implementation challenges and extension opportunities. *J Pharm Sci* 2004;93:1375–81.
14. Kesselheim AS, Stedman MR, Bublick EJ, Gagne JJ, Misono AS, Lee JL, *et al.* Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. *Drugs* 2010;70:605–21.
15. Dylst P, Simoons S. Generic medicine pricing policies in Europe: current status and impact.

- Pharmaceuticals 2010;3:471–81.
16. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, *et al.* What do primary care patients think about generic drugs? *Int J Clin Pharmacol Ther* 2005;43:472–9.
17. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, *et al.* Policies to enhance prescribing efficiency in Europe: findings and future implications. *Front Pharmacol* 2010;1:141.
18. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. *Expert Rev Pharmacoecon Outcomes Res* 2013;13:59–72.
19. Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. *Health Policy* 2007;82:366–74.
20. Kjoenniksen I, Lindbaek M, Granas AG. Patients' attitudes to and experiences of generic drug substitution in Norway. *Pharm World Sci* 2006;28:284–9.
21. Faasse K, Cundy T, Gamble G, Petrie KJ. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. *Psychosom Med* 2013;75:90–6.
22. Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. *Postgrad Med J* 2013;89:540–6.
23. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. *Ann Intern Med* 2014;161:96–103.
24. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, *et al.* Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. *JAMA Intern Med* 2013;173:202–8.
25. Olsson E, Källemark Sporrang S. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. *Int J Pharm Pract* 2012;20:377–83.
26. Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. *Health Policy* 2014;116:214–23.
27. Hassali MA, Shafie AA, Jamshed S, Ibrahim MIM, Awaisu A. Consumers' views on generic medicines: a review of the literature. *Int J Pharm Pract* 2009;17:79–88.
28. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. *JAMA* 2002;287:622–7.
29. Colloca L, Barsky AJ. Placebo and nocebo effects. *N Engl J Med* 2020;382:554–61.
30. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. *Ann Pharmacother* 2011;45:31–8.
31. Straka RJ, Keohane DJ, Liu LZ. Potential clinical and economic impact of switching branded medications to generics. *Am J Ther* 2017;24:e278–89.